Overall, according to the gene expression data it seems that the difference in response to miR-125b replacement therapy between the two colon cancer cells is mainly caused by the differential modulation of TP53 expression and implicitly its mutational status. The gene discussed is TP53; the disease is malignant colon neoplasm.